SCHOTT Pharma AG & Co. KGaA
1SXP
ISIN DE000A3ENQ51 / Valor 128964250
SCHOTT Pharma AG & Co. KGaA
UMushroom community rating:
About company
SCHOTT Pharma AG & Co. KGaA, a subsidiary of SCHOTT AG, specializes in the production of drug containment and delivery systems, including pharmaceutical syringes, cartridges, vials, and ampoules. With a global presence in 34 countries and 16 GMP-compliant manufacturing sites, the company produces over 13 billion drug containers annually, catering to the needs of the pharmaceutical industry. Employing more than 4,700 professionals across North America, Europe, Asia, and Latin America, SCHOTT Pharma collaborates with leading industry partners to ensure the safe, fast, and reliable delivery of medicines. The company operates under the ownership of the Carl Zeiss Foundation and is headquartered in Mainz, Germany. In the fiscal year 2021, SCHOTT Pharma contributed to SCHOTT AG's overall sales of 2.5 billion euros, leveraging its expertise in borosilicate glass and high-grade pharmaceutical COC polymer to meet diverse drug formulation requirements.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (03.10.2025):
SCHOTT Pharma AG & Co. KGaA reported solid financial results for the third quarter of 2025, demonstrating stable revenue growth and improved profitability. The company achieved a 1% year-over-year increase in revenues to EUR 256 million, alongside a robust EBITDA margin of 32.4%. High-value solutions now constitute 60% of total revenues, underscoring SCHOTT Pharma’s strategic focus on premium product offerings. The company remains optimistic about achieving its full-year targets, anticipating an organic revenue growth of approximately 6.0% and an EBITDA margin around 28.0% for fiscal year 2025.
Revenue Growth
Enhanced EBITDA Margin
Growth in High-Value Solutions
High-value solutions (HVS) accounted for 60% of SCHOTT Pharma’s revenues in Q3 2025, up from 55% in the previous year. This increase reflects the company’s ongoing strategy to focus on premium product offerings, with sterile solutions and specialty vials being key contributors. HVS now represents a significant portion of both quarterly and year-to-date revenues, supporting SCHOTT Pharma’s mid-term goal of generating over 60% of revenue from high-margin products.
Segment Performance
The Drug Containment Solutions (DCS) segment saw revenues grow by 4% to EUR 142 million, approaching the record set in Q2 2023. This growth was driven by strong demand for sterile cartridges and specialty vials for biologics and advanced therapies. Conversely, the Drug Delivery Systems (DDS) segment experienced a slight decline of 2% in revenues to EUR 114 million, primarily due to reduced demand for polymer syringes, partially offset by growth in prefillable glass syringes.
Innovation and Sustainability Initiatives
Expansion Projects
Outlook and Guidance
Leadership Update
Key figures
Performance
Volatility
3140 M
Market cap (USD)
41,558
Daily traded volume (Shares)
25.1 / 24.7
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
